ArticleMediators of inflammation2002
IL-1 stimulates ceramide accumulation without inducing apoptosis in intestinal epithelial cells.
Article in Mediators of inflammation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults.World journal of gastroenterology · 2008Trial
- Metabolomic Profiling of Fecal Samples Reveals Distinct Signatures Associated with Disease Phenotypes and Locations in Crohn's Disease.Digestive diseases and sciences · 2026Article
- Article
- Article
- The Role of Lipids in the Regulation of Immune Responses.Nutrients · 2023Review
- Expression of the methylcytosine dioxygenase ten-eleven translocation-2 and connexin 43 in inflammatory bowel disease and colorectal cancer.World journal of gastroenterology · 2022Article
- Adipocyte Ceramides-The Nexus of Inflammation and Metabolic Disease.Frontiers in immunology · 2020Review
- Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency.Scientific reports · 2018Article
- Cross-talk between intestinal epithelial cells and immune cells in inflammatory bowel disease.Scientific reports · 2016Article
- Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces.Mediators of inflammation · 2016Review
- Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome.World journal of gastroenterology · 2009Article
- Apoptosis and the activity of ceramide, Bax and Bcl-2 in the lungs of neonatal rats exposed to limited and prolonged hyperoxia.Respiratory research · 2006Article
- Regulation of nuclear factor-kappaB in intestinal epithelial cells in a cell model of inflammation.Mediators of inflammation · 2003Article
- Ceramide: second messenger or modulator of membrane structure and dynamics?The Biochemical journal · 2003Review
- Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease.Mediators of inflammationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn inflammatory bowel disease (IBD), cytokine levels (such as interleukin-1 (IL-1)) are elevated. We have shown previously that IL-1 activates phospholipid signaling pathways in intestinal epithelial cells (EEC), leading to increased ceramide levels.
aimTo determine whether ceramide induces apoptosis in IEC.
methodsApoptosis was evaluated by annexin-V binding or Hoechst nuclear staining. Levels of bcl-2, bcl-x, bax, p53 and p21 were determined by Western blotting, and celi cycle analysis was determined by flow cytometry.
resultsIL-1 increased ceramide accumulation in a time-dependent and concentration-dependent manner with a peak response at 4 h, with [IL-1] = 30 ng/ml. Neither IL-1 nor ceramide induced apoptosis in EEC, but they increased bcl-2 levels and decreased bax and p21 levels without affecting bcl-x and p53 levels. They also caused a slight but significant increase in the G2/M phase. These data suggest a role for ceramide in IBD and suggest a possible mechanism for the enhanced tumorigenic activity in IBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.